Reports Q1 reveue $6.7B, consensus $6.81B. “Gilead (GILD) had a strong start to the year driven by excellent commercial and clinical execution ...

In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed HIV with a single weekly oral dose, raising the hope of a new treatment option for patients.

As previously reported, Cantor Fitzgerald analyst Carter Gould upgraded Gilead (GILD) to Overweight from Neutral with a price target of $125, ...

GSK has fired a shot across the bows of Gilead Sciences' HIV juggernaut Biktarvy, with new data showing its rival therapy Dovato is as effective but causes less weight gain. The results of the ...

Gilead has a strong HIV franchise with flagship treatment Biktarvy driving the growth. The company’s efforts to develop innovative HIV treatments for prevention are impressive as well.

Cost assistance is available through the Advancing Access program offered by Biktarvy’s manufacturer, Gilead Sciences, Inc. Assistance is also available through the Ryan White HIV/AIDS Program.

Vertex is expected to benefit from remaining the market leader in cystic fibrosis treatments as well as expansion into acute pain with suzetrigine, which has an FDA action date of Jan. 30, 2025 ...

Gilead has a strong HIV franchise with flagship treatment Biktarvy driving the growth. The company’s efforts to develop innovative HIV treatments for prevention are impressive as well.

Gilead Sciences (NASDAQ ... and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment ...

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Gilead is the maker of Biktarvy and Descovy, two antiretroviral drugs used to prevent and treat the virus. In January, the company settled a lawsuit with the CDC claiming Gilead refused to license ...